OverviewSuggest Edit

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
TypePublic
Founded2007
HQCambridge, US
Websitedicerna.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2018)78(+78%)
Job Openings21
Revenue (FY, 2018)$6.2 M(+172%)
Share Price (Nov 2019)$19.3 (-4%)

Key People/Management at Dicerna Pharmaceuticals

Douglas M. Fambrough

Douglas M. Fambrough

President and Chief Executive Officer
Bob D. Brown

Bob D. Brown

Chief Scientific Officer, Senior Vice President
Jack Green

Jack Green

CFO
Jennifer Lockridge

Jennifer Lockridge

Senior Vice President, Program Development
David Miller

David Miller

Senior Vice President, Corporate Operations
Ralf Rosskamp

Ralf Rosskamp

Chief Medical Officer
Show more

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridgepark Dr
Show all (1)

Dicerna Pharmaceuticals Financials and Metrics

Dicerna Pharmaceuticals Revenue

Dicerna Pharmaceuticals's revenue was reported to be $6.18 m in FY, 2018
USD

Revenue (Q3, 2019)

8.0m

Net income (Q3, 2019)

(30.8m)

EBIT (Q3, 2019)

(32.7m)

Market capitalization (15-Nov-2019)

1.3b

Closing stock price (15-Nov-2019)

19.3

Cash (30-Sep-2019)

47.2m

EV

1.3b
Dicerna Pharmaceuticals's current market capitalization is $1.3 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

184.0k295.0k2.3m6.2m

Revenue growth, %

60%

General and administrative expense

15.6m19.2m18.3m25.9m21.7m

R&D expense

29.5m44.0m41.7m37.0m45.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

184.0k162.0k133.0k252.0k474.0k1.5m1.5m3.1m5.7m8.0m

General and administrative expense

2.8m4.4m3.7m5.4m4.5m4.9m4.5m4.7m4.3m5.5m6.3m6.7m7.5m4.8m5.4m9.7m8.8m10.6m

R&D expense

5.3m6.8m7.5m8.7m11.9m12.1m11.3m11.0m10.1m8.9m9.3m9.0m9.9m10.3m11.7m21.6m22.8m30.1m

Operating expense total

8.1m11.2m11.2m14.1m16.4m17.0m15.7m15.7m14.4m14.4m15.6m15.7m17.4m15.1m17.0m31.3m31.7m40.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

26.1m56.1m20.9m68.8m54.2m

Accounts Receivable

254.7m805.4k100.0m

Prepaid Expenses

3.3m2.9m

Inventories

1.2m1.5m2.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

133.8m77.7m31.8m22.6m25.9m52.9m27.6m29.2m32.5m22.9m38.8m31.0m43.0m42.4m46.4m160.1m100.3m47.2m

Accounts Receivable

3.0m

Prepaid Expenses

906.0k1.0m856.0k1.4m1.7m1.7m1.2m1.5m1.8m2.7m3.0m3.9m2.4m3.7m3.1m2.2m5.0m4.7m

Current Assets

134.7m101.3m93.7m89.1m96.7m95.7m81.8m70.7m59.4m36.2m91.7m79.8m101.8m87.6m183.5m373.4m350.2m320.4m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(47.9m)(62.8m)(59.5m)(60.0m)(88.9m)

Depreciation and Amortization

848.0k727.0k840.0k778.0k

Inventories

(44.3m)

Accounts Payable

(97.0k)1.4m1.6m626.0k(1.2m)
USDY, 2019

EV/EBIT

-39 x

EV/CFO

89.5 x

Financial Leverage

2.5 x
Show all financial metrics

Dicerna Pharmaceuticals Online and Social Media Presence

Embed Graph

Dicerna Pharmaceuticals News and Updates

Dicerna Pharmaceuticals Blogs

Dicerna™ to Present at the Stifel 2019 Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive

Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress

— Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S.

Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019 Content Import Mon, 11/04/2019 - 07:30 Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019 Nov 4, 2019 This re…

Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection Content Import Thu, 10/31/2019 - 06:30 Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis…

Dicerna™ to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two investor conferences in

Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth

Company Announces Retirement of Board of Director Veteran Dennis Langer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 19, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of
Show more

Dicerna Pharmaceuticals Frequently Asked Questions

  • When was Dicerna Pharmaceuticals founded?

    Dicerna Pharmaceuticals was founded in 2007.

  • Who are Dicerna Pharmaceuticals key executives?

    Dicerna Pharmaceuticals's key executives are Douglas M. Fambrough, Bob D. Brown and Jack Green.

  • How many employees does Dicerna Pharmaceuticals have?

    Dicerna Pharmaceuticals has 78 employees.

  • What is Dicerna Pharmaceuticals revenue?

    Latest Dicerna Pharmaceuticals annual revenue is $6.2 m.

  • What is Dicerna Pharmaceuticals revenue per employee?

    Latest Dicerna Pharmaceuticals revenue per employee is $79.2 k.

  • Who are Dicerna Pharmaceuticals competitors?

    Competitors of Dicerna Pharmaceuticals include TxCell, Bluebird Bio and CytRx.

  • Where is Dicerna Pharmaceuticals headquarters?

    Dicerna Pharmaceuticals headquarters is located at 87 Cambridgepark Dr, Cambridge.

  • Where are Dicerna Pharmaceuticals offices?

    Dicerna Pharmaceuticals has an office in Cambridge.

  • How many offices does Dicerna Pharmaceuticals have?

    Dicerna Pharmaceuticals has 1 office.